Wang Haw-En, Lin Chih-Lang, Pan Tai-Long, Yeh Chau-Ting
Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.
Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
In Vivo. 2018 Jul-Aug;32(4):955-960. doi: 10.21873/invivo.11334.
BACKGROUND/AIM: Our previous cDNA microarray study revealed increased cellular mRNA levels of a panel of genes, including kallikrein-8 (KLK8), after long-term telbivudine treatment in chronic hepatitis B patients. The aim of this study was to verify whether serum protein levels of KLK8, a cancer-related enzyme, are indeed increased after telbivudine treatment.
A total of 83 chronic hepatitis B patients receiving telbivudine for >2 years were retrospectively analyzed. Serum KLK8 protein and estimated glomerular filtration rate (eGFR) changes were compared before and after treatment.
Both serum KLK8 protein and eGFR increased significantly after long-term telbivudine treatment (paired t-test: KLK8, p<0.001; eGFR, p=0.001). No direct correlation was found between KLK8 increase and eGFR change. However, eGFR change was positively associated with post-treatment KLK8 levels following adjustment for body height (p<0.001).
Telbivudine treatment resulted in increased levels of serum KLK8 protein. Furthermore, eGFR increase was associated with body height-adjusted, post-treatment KLK8 levels.
背景/目的：我们之前的cDNA微阵列研究显示，在慢性乙型肝炎患者长期接受替比夫定治疗后，一组基因（包括激肽释放酶8，KLK8）的细胞mRNA水平升高。本研究旨在验证癌症相关酶KLK8的血清蛋白水平在替比夫定治疗后是否确实升高。
对83例接受替比夫定治疗超过2年的慢性乙型肝炎患者进行回顾性分析。比较治疗前后血清KLK8蛋白和估计肾小球滤过率（eGFR）的变化。
长期替比夫定治疗后，血清KLK8蛋白和eGFR均显著升高（配对t检验：KLK8，p<0.001；eGFR，p=0.001）。未发现KLK8升高与eGFR变化之间存在直接相关性。然而，在调整身高后，eGFR变化与治疗后KLK8水平呈正相关（p<0.001）。
替比夫定治疗导致血清KLK8蛋白水平升高。此外，eGFR升高与调整身高后的治疗后KLK8水平相关。
